Ardelyx Inc ARDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $5.09
- Day Range
- $4.98–5.12
- 52-Week Range
- $4.08–8.40
- Bid/Ask
- $5.03 / $5.10
- Shares Outstanding
- 247.03M
- Market Cap
- $1.26B
- Volume/Avg
- 4M / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.95
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 489
- Website
- https://www.ardelyx.com
Valuation
|
Metric
|
ARDX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.64 |
Price/Sales | 2.95 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ARDX
|
|---|---|
Quick Ratio | 2.93 |
Current Ratio | 3.49 |
Interest Coverage | −0.99 |
Quick Ratio
ARDX
Profitability
|
Metric
|
ARDX
|
|---|---|
Return on Assets (Normalized) | −3.74% |
Return on Equity (Normalized) | −11.75% |
Return on Invested Capital (Normalized) | 1.50% |
Return on Assets
ARDX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!jx?P<@ | LOCK|p&&H | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%?<%!S | LOCK|F$ZN@ | $71B | |||
| argenx SE ADR
ARGX
| LOCK|f#!Hs># | LOCK|YrP | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|HV??H@ | LOCK|sR | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&gw@d& | LOCK|%kM! | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|jv?&F$&W | LOCK|$&&d | $26B | |||
| Moderna Inc
MRNA
| LOCK|N%Y^>J^ | LOCK|n!R | $24B | |||
| Incyte Corp
INCY
| LOCK|f%!ZRn | LOCK|KZ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Hp#&&> | LOCK|v$ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|T!#Bqv> | LOCK|<> | $16B |
United States